High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial

BACKGROUND: The use of Lamivudine in chronic hepatitis B (CHB) is well known, however the reported rate of HBeAg sero-conversion and its durability post-treatment have varied considerably. We undertook the present study to study the effect of Lamivudine on HBeAg loss and seroconversion rates in Indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexander, George, Baba, Chalamalasetty S, Chetri, Kamal, Negi, TS, Choudhuri, Gourdas
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242224/
https://www.ncbi.nlm.nih.gov/pubmed/16164746
http://dx.doi.org/10.1186/1471-230X-5-29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242224/
https://www.ncbi.nlm.nih.gov/pubmed/16164746
http://dx.doi.org/10.1186/1471-230X-5-29

Ejemplares similares